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Abstract   
Background Combination therapies with cetuximab (Erbitux®, Merck Serono UK Ltd) and panitumumab 
(Vectibix®, Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer (mCRC) 
who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the rat sarcoma (RAS) family. 
Objective To estimate the cost effectiveness of these drugs in patients with previously untreated RAS wild-type 
(WT) (i.e., non-mutated) mCRC, not eligible for liver resection at baseline, from the UK National Health 
Service (NHS) and Personal Social Services perspective.  
Methods We constructed a partitioned survival model to evaluate the long-term costs and benefits of cetuximab 
and panitumumab combined with either FOLFOX (folinic acid, fluorouracil and oxaliplatin) or FOLFIRI 
(folinic acid, fluorouracil and irinotecan) vs. FOLFOX or FOLFIRI alone. The economic analysis was based on 
three randomized controlled trials. Costs and quality-adjusted life-years (QALYs) were discounted at 3.5% per 
annum.  
Results Based on the evidence available, both drugs fulfil the National Institute for Health and Care Excellence 
(NICE) End-of-Life criteria. In the analysis assuming discount prices for the drugs from Patient Access 
Schemes (PASs) agreed by the drug manufacturers with the Department of Health, predicted mean incremental 
cost-effectiveness ratios for cetuximab+FOLFOX, panitumumab+FOLFOX, and cetuximab+FOLFIRI 
compared to chemotherapy alone appeared cost effective at NICE’s threshold of £50,000 per QALY gained, 
applicable to End-of-Life treatments.  
Conclusion Cetuximab and panitumumab were recommended by NICE for patients with previously untreated 
RAS WT mCRC, not eligible for liver resection at baseline, for use within the NHS in England. Both treatments 
are available via the UK Cancer Drugs Fund. 
 
  
Key Points for Decision Makers 
In metastatic colorectal cancer (mCRC), mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the 
rat sarcoma (RAS) family may reduce response to monoclonal therapies with cetuximab and panitumumab. 
Therefore, these therapies may not be effective in patients with such mutations.  
Under Patient Access Schemes (PASs) agreed by the manufactures of these drugs with the UK Department of 
Health, cetuximab and panitumumab given in combination with either FOLFOX or FOLFIRI appear cost 
effective in previously untreated mCRC patients not eligible for liver resection at baseline, who do not have 
such mutations.  
The NICE Appraisal Committee recommended cetuximab and panitumumab in combination with either 
FOLFOX or FOLFIRI for this patient population. The drugs are recommended only when the companies 
provide them with the PAS discounts.  
1 Introduction 
Colorectal, also known as bowel, cancer is any cancer of the colon (large bowel), rectum and appendix. It is the 
fourth most common cancer, and the second most common cause of cancer death in the UK [1]. Approximately 
41,300 new cases of colorectal cancer (CRC) were reported in the UK in 2014. CRC primarily affects adults, 
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with the median age of patients at diagnosis of over 70 years. Metastatic colorectal cancer (mCRC) refers to 
disease that has spread beyond the large intestine and nearby lymph nodes to other parts of the body, most often to the 
liver. Between 10% and 25% of people with CRC have metastatic disease at the time of diagnosis, and about 
50% of patients who have had surgery for early stage disease eventually develop metastases [2]. 
Treatment options for mCRC include surgery, chemotherapy, radiotherapy and supportive care. Research 
suggests that resection of liver metastases from colorectal cancer can substantially increase overall survival; for 
those patients who do not undergo resection, survival prognosis is relatively poor. The overall five-year survival 
of mCRC patients (diagnosed 1996-2002) in England was 6.6% [3], while the survival rate in patients who 
underwent colorectal liver resection (starting April 1988 through July 2002) was 33% [4]. Typically, liver 
resection would be performed in patients with metastases confined to the liver. As reported in Adam et al. 
(2009) [4], about 80% of mCRC patients with colorectal liver metastases have unresectable disease at diagnosis. 
Chemotherapy treatment can significantly downsize the primary unresectable tumor, and thus offer the 
possibility of curative resection and therefore prolong survival. For the majority of patients, however, surgery 
with curative intent following downsizing chemotherapy is not an option due to the widespread nature of their 
disease and/or poor suitability for surgery. Such patients are treated with palliative intent to improve the 
duration and the quality of the individual’s remaining life.  
The National Institute for Health and Care Excellence (NICE) clinical guideline 131 [5] recommends 
chemotherapy options including fluorouracil and folinic acid in combination with oxaliplatin (FOLFOX); 
tegafur in combination with fluorouracil and folinic acid; capecitabine in combination with oxaliplatin 
(XELOX); and capecitabine alone. In practice, fluorouracil and folinic acid may also be used in combination 
with irinotecan (FOLFIRI) in people for whom oxaliplatin is not suitable. According to our clinical expert, Dr 
Mark Napier, FOLFOX and FOLFIRI are offered to mCRC patients in the NHS most often: they account for 
~30% and ~10% of all first-line treatments, respectively.  
Chemotherapy may be combined with biological agents, cetuximab (Erbitux®, Merck Serono UK Ltd) [6] and 
panitumumab (Vectibix®, Amgen UK Ltd) [7]. These are monoclonal antibodies targeting the epidermal growth 
factor receptor (EGFR), recognized as an important player in the development of colorectal cancer. Recent 
research suggests that mutations in exons 2, 3 and 4 of the genes, Kristen rat sarcoma (KRAS) and 
neuroblastoma rat sarcoma (NRAS) (which belong to oncogenes from the rat sarcoma, RAS, family [8, 9]), are a 
strong predictor of resistance to EGFR-targeted drugs [2, 10-15]; and therefore such therapies may not be 
effective in patients with the RAS mutations, which constitute about 50% of all mCRC patients (prevalence of 
the RAS mutations is detailed in Online Resource 1). In light of these developments, the marketing 
authorizations for cetuximab [16] and panitumumab [17] were updated by the European Medicines Agency in 
2013 to restrict use to patients without KRAS and NRAS mutations in exons 2, 3 and 4. In 2015, NICE invited 
the manufacturers of these drugs to submit evidence for their clinical and cost effectiveness, in combination with 
chemotherapy, in mCRC patients with previously untreated RAS wild-type (WT) (i.e., non-mutated) tumors, 
who are not eligible for liver surgery at baseline, as part of the Institute’s Multiple Technology Appraisal 
(MTA) process [18, 19]. At the time of this technology appraisal (TA439), cetuximab had marketing 
authorization for use in combination with FOLFOX or FOLFIRI for patients with liver metastases (see NICE 
TA176 [20]), while panitumumab had a UK marketing authorization for use in combination with FOLFOX [21]; 
both drugs were available via the UK Cancer Drugs Fund for first-line treatment of mCRC without mutations in 
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exon 2 of the KRAS oncogene only (refer to [20] and [21] for further details on the Marketing Authorization 
criteria).  
The work reported here builds on the previous TA176. The Peninsula Technology Assessment Group 
(PenTAG), commissioned to act as the Assessment Group in this MTA, prepared an independent health 
economic assessment of these technologies, which was submitted to NICE on 7 August, 2015. After that, seven 
additional economic analyses requested by NICE were conducted by PenTAG. The project was completed in 
March, 2017. A summary of the most recent analysis, dated January 2017, and a summary of the NICE guidance 
are reported in this manuscript. Further details are available on the NICE website [22].  
2 Methods 
In our report to NICE, results were presented for the overall population of mCRC patients, and a subgroup of 
patients with metastases confined to the liver at the diagnosis of metastatic disease, which comprised about a 
quarter of all mCRC patients. In the previous NICE guidance, TA176 [20], the liver metastases subgroup was 
considered a distinct subgroup of mCRC patients. In this appraisal, however, the NICE Committee concluded 
based on advice from commentators and consultees that people with liver-only metastases were no longer a 
distinct subgroup in current clinical practice. Here, we present the results for the overall mCRC patient 
population; for the analysis relevant to the liver-metastases subgroup refer to Committee papers, dated 2 March, 
2017 [22]. 
 
2.1 Clinical effectiveness  
We conducted systematic reviews of clinical and cost effectiveness using a pre-specified protocol registered in 
PROSPERO (CRD #42015016111) [23]. A network meta-analysis was performed based on five randomized 
controlled trials (RCTs) identified during our systematic literature review of clinical evidence (see Tables 1-4, 
Online Resource 2). Since it was not possible to construct a complete network for FOLFOX- and FOLFIRI-
containing chemotherapy regimens due to the lack of randomized evidence connecting these treatments, two 
separate networks were generated (Fig. 1). Data from three RCTs - PRIME [11], PEAK [13], and OPUS [24] - 
contributed to the estimation of clinical effectiveness of FOLFOX-containing regimens; effectiveness of 
FOLFIRI-containing treatments was based on the CRYSTAL [25] and FIRE-3 [12] RCTs. No evidence was 
identified on the effectiveness of panitumumab plus FOLFIRI in mCRC patients. 
Bevacizumab (BEV)+FOLFOX and BEV+FOLFIRI trials were used in the network meta-analysis to complete 
the network; bevacizumab arms, however, were excluded from the base case, since they had not been 
recommended by NICE for first-line treatment of metastatic colorectal cancer; bevacizumab-containing 
regimens for first-line mCRC had been delisted from the UK Cancer Drugs Fund [26, 27]. The cost-utility of 
these treatments was examined in scenario analyses (refer to [22] for further details). 
In the base-case analysis, PRIME and CRYSTAL were considered baseline trials for the FOLFOX and 
FOLFIRI networks, respectively (Fig. 1). PRIME was selected as a baseline trial since it had a larger patient 
population of interest (512 RAS WT patients) compared to the other relevant RCT, OPUS (which had only 87 
patients). (Fig. 1). The CRYSTAL RCT was chosen since the only treatments compared in this trial were 
cetuximab (CET)+FOLFIRI and FOLFIRI; the other relevant RCT, FIRE-3, considered BEV+FOLFIRI, which 
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was examined in sensitivity analyses only. In the FOLFOX regimens network, FOLFOX was the baseline 
treatment, while FOLFIRI was the baseline treatment in the FOLFIRI regimens network. 
The network meta-analyses were undertaken within a Bayesian framework in WinBUGS (version 1.4.3). Vague 
priors were assumed for the model parameters. For the analysis of progression-free survival (PFS), overall 
survival (OS) and objective response rate (ORR), models with a normal likelihood and identify link were used, 
while adverse events (AEs) were modelled using a binomial likelihood and logit link [28]. For the analysis of 
the AEs, where there were no events reported in a study arm, a continuity correction of 0.5 was added to every 
cell for that particular study [28]. Due to the small number of RCTs contributing to each network, only fixed 
effects models were considered. Markov Chain Monte Carlo simulations with three chains were run for 150,000 
iterations with a burn-in of 50,000. Convergence was assessed using the autocorrelation, density and trace plots 
for all monitored variables, and by checking that each chain was sampling from the same posterior distribution. 
The results of these analyses are presented in Online Resource 2. 
 
Fig. 1 FOLFOX and FOLFIRI treatment networks. These treatments were considered in our base case, with the exception of 
those containing bevacizumab. * Baseline trial, BEV bevacizumab, CET cetuximab, FOLFOX folinic acid + fluorouracil + 
oxaliplatin, FOLFIRI folinic acid +fluorouracil + irinotecan, RCT randomized control trial 
 
The clinical evidence for cetuximab and panitumumab was derived from post hoc subgroup analyses for patients 
with RAS WT metastatic colorectal cancer as no RCTs with RAS WT mCRC intention-to-treat population were 
identified in the systematic literature review. Allocation of patients to subgroups was based on re-evaluation for 
RAS status of tumor samples from the KRAS WT Exon 2 population. The subgroups of patients with RAS WT 
and RAS mutated mCRC were generally similar in prognosis at baseline, allocation concealment, blinding, 
outcome reporting and loss to follow-up [22]. 
In clinical practice, FOLFOX may be administered in different regimens, commonly FOLFOX4 (oxaliplatin, 85 
mg/m²; fluorouracil, 2,000 mg/m²; and leucovorin, 400 mg/m²) and FOLFOX6 (oxaliplatin, 100 mg/m²; 
fluorouracil, 2,800 mg/m²; and leucovorin, 400 mg/m²). These regimens are regarded as similar in effectiveness 
(see our report [29]). Based on clinical opinion, we considered FOLFOX6 in the base case, as this regimen is 
more commonly used in England [29] (it requires less administration time and is therefore less costly).  
Direct evidence suggests a treatment effect in favor of the addition of cetuximab or panitumumab to 
chemotherapy compared with chemotherapy alone. Addition of cetuximab to FOLFOX resulted in increased 
median OS of 19.8 months vs. 17.8 months for FOLFOX alone [24]. However, the difference in survival was 
not statistically significant. CET+FOLFIRI demonstrated a statistically significant increase of 8.2 months in 
median OS vs. FOLFIRI alone (28.4 months vs. 20.2 months, respectively) [25]. Median OS of patients on 
panitumumab (PAN)+FOLFOX was 25.8 months vs. 20.2 months for patients treated with FOLFOX alone [30], 
with the difference in survival being statistically significant. The combination therapies with FOLFOX and 
FOLFIRI were shown to also improve PFS in mCRC patients. A summary of direct and indirect evidence of 
efficacy and safety outcomes for CET+FOLFOX, CET+FOLFIRI, PAN+FOLFOX and the comparative 
treatments is provided in Tables 5 and 6 (Online Resource 2). 
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2.2 Cost effectiveness 
2.2.1 Treatments and comparators 
In our base-case analysis, treatments with CET+FOLFOX, PAN+FOLFOX, and FOLFOX (FOLFOX network); 
and CET+FOLFIRI and FOLFIRI (FOLFIRI network) were compared.  
2.2.2 Model structure   
Of 1,979 search results obtained in our systematic review of cost effectiveness, no studies completely answered 
the decision problem addressed in this appraisal. A de novo discrete-time partitioned survival model [31] was 
constructed to evaluate the cost-utility of combination treatments with cetuxmab and panitumumab over the life 
span of patients with metastatic colorectal cancer (Fig. 2). The model was implemented in Microsoft Excel 
(2013). 
Fig. 2 Model structure. * For CET+FOLFIRI and FOLFIRI only. BSC best supportive care, CET cetuximab, FOLFOX folinic 
acid + fluorouracil + oxaliplatin, FOLFIRI folinic acid +fluorouracil + irinotecan, DFS disease-free survival (defined as the 
length of time after primary treatment for the cancer that the patient survives without any signs or symptoms of the disease), 
PFS progression-free survival (defined as the length of time during and after the treatment of the disease, that a patient lives 
with the disease but it does not get worse) 
 
The model simulates a cohort of people with RAS WT mCRC starting on first-line treatment. The treatment is 
given until disease progression with the exception of CET+FOLFIRI and FOLFIRI: for these treatment arms, 
there is a period in first-line PFS (denoted by “PFS* (no treatment)” in Fig. 2) during which patients are not on 
active therapy, since in the relevant RCT, CRYSTAL, the mean duration of these treatments was less than the 
mean time in PFS. As liver resection is likely to increase patient survival substantially, it was important to take 
account of this effect in the economic analysis. In the model, it is assumed that patients, who become eligible for 
resection after active first-line treatment, undergo one or more surgeries to resect liver metastases (this pathway 
is shown under “Resection” in Fig. 2). Liver surgery in mCRC patients is usually performed 12-16 weeks after 
treatment initiation [32, 20]. For simplicity, all resections are modelled at the start of simulation, with a loss of 
accuracy of ~1% due to inaccuracy in the timing, and hence discounting, of costs and quality-adjusted life-years 
(QALYs) for resected patients. Patients whose tumor could not be resected despite the downsizing therapy are 
given second-line treatment upon disease progression followed by third-line best supportive care (BSC) after 
further progression (see “No resection”, Fig. 2). In the model, patients whose liver resection was successful (R0-
resection) are not actively treated during disease-free survival (DFS), and receive BSC treatment on disease 
progression, which is the same as the third-line BSC for non-resected patients. Those patients whose resection 
was not successful are given the same treatment as non-resected patients, i.e., second- and third-line therapies 
(Fig. 2). Of note, KM survival data, used in our analysis, already include resection survival failure, and therefore 
the resection failure rate is not modelled separately. “Death” is an absorbing state in this model. Circular arrows 
in Fig.2 denote that patients can remain in a health state at the end of each model cycle. Since in our analysis we 
employed the partitioned survival approach [31], state transitions depicted by straight arrows in Fig.2 were not 
modelled explicitly. In the model, all patients are assumed aged 63 at the start of first-line treatment, with 66% 
of patients male, which is consistent with baseline patient characteristics from the pivotal RCTs (in the model, 
these affect age-related utilities and background mortality); the impact of these assumptions on the results was 
examined in sensitivity analyses.  
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The primary health outcomes in the model are life-years attained in each treatment, expressed in QALYs; the 
main economic outcome is the incremental cost-effectiveness ratio (ICER). Total per patient costs and QALYs 
for each treatment are estimated over the model time horizon of 30 years. Future costs and benefits are 
discounted at 3.5% per annum. The perspective is that of the National Health Service (NHS) and Personal Social 
Services (PSS) in accordance with the NICE Reference Case [19]. The model cycle is one month, with a half-
cycle correction applied using the mid-cycle method [33]. 
Two approaches to modelling survival and time on different treatments were considered: one approach, 
implemented in the main analysis, was based completely on data from the clinical trials; the other approach, 
employed in a scenario analysis, assumed only progression-free survival on first-line drugs from the RCTs, with 
post-progression survival estimated from published literature. Of note, the base-case analysis reported to NICE 
on 7 August, 2015, was based on the second approach. A comparative analysis of these approaches is provided 
in Online Resource 3.  
2.2.3 Treatment effectiveness 
In the model, the difference in clinical effectiveness between the first-line treatments is presented by the 
difference in first-line PFS, the difference in OS, and the rates of liver resection and adverse events.  
Disease-free and overall survival post resection 
In the previous assessment, TA176, overall survival after liver resection with curative intent was derived from 
Adam et al. (2004) [32]. We performed a forward reference search for this publication in PubMed to identify 
more recent studies reporting survival after liver resection for colorectal metastases. This yielded two studies: 
Adam et al. 2009 [4] and Adam et al. 2012 [34]. Importantly, the key information on patient population (such as 
age and gender composition), OS, DFS after liver resection, and the frequency of liver surgeries for colorectal 
metastases were reported in Adam et al. (2004) [32] only. Therefore, we selected Adam (2004) [32] as the 
evidence source of these estimates. The choice of study, however, had little impact on cost-effectiveness results. 
With no evidence to the contrary, it was assumed that DFS and OS in resected patients were independent of 
first-line treatment. Weibull and log-logistic models were fitted to survival data using the method of least 
squares. General background non-CRC mortality was modelled explicitly since the DFS reported in Adam et al. 
[32] was immature, with about 20% of patients being still in pre-progression state at the end of the study 
observation period. The Weibull model for PFS was selected for the base-case analysis as it provided the most 
plausible predictions of disease-free survival eight years after the start of treatment (Fig. 3). The estimated mean 
DFS was 4.1 years assuming the Weibull distribution, which is substantially greater than predicted mean PFS 
for unresected patients, which varied from 0.6 year to 1 year depending on treatment (see Tables 1 and 2, Online 
Resource 7). For the base case, the log-logistic model of OS was selected, as OS predicted by this model was 
consistent with the Weibull model for DFS (i.e., OS was always greater than DFS). Assuming a 30 year model 
time horizon, the estimated mean OS in resected patients was 6.2 years. 
 
Fig. 3 DFS and OS post resection. a A Kaplan-Meier estimate of DFS in resected mCRC patients from Adam et al. (2004) 
[32], and a Weibull model for DFS from the base-case analysis, extrapolated beyond the observational period of 10 years;     
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b A Kaplan-Meier estimate of survivor function in resected mCRC patients from Adam et al. (2004) [32], and a log-logistic 
model for OS from the base-case analysis. PenTAG Peninsula Technology Assessment Group, OS overall survival, DFS 
disease-free survival 
 
  
Progression-free and overall survival for non-resected patients  
First-line progression-free survival for non-resected patients 
 
PFS for non-resected patients was estimated as outlined below (a detailed description is provided in Section 1.2, 
Online Resource 4): 
A. First, we extrapolated PFS for each treatment arm from the RCTs. 
B. Second, the mean PFS and the standard error of the mean were calculated from each extrapolated PFS curve. 
C. Next, we performed a mixed-treatment comparison (MTC) on the mean PFS. We chose to base the MTC on 
mean survival, not hazard ratio, in order to avoid making an additional assumption on proportional hazard. 
D. Then, the mean DFS for patients post resection was estimated from Adam et al. (2004) [32] as described 
above (this was assumed to apply in all modelled treatment arms). 
E. Finally, PFS for non-resected patients was derived from the mean PFS for all patients (Step C), the mean 
DFS for resected patients (Step D), and the proportion of resected patients in each treatment arm, assuming that 
PFS for non-resected patients has the same parametric form for all treatment arms (Weibull) with the shape 
parameter estimated in Step A. Another important assumption made here is that PFS in resected patients could 
be approximated by DFS.  However, inaccuracy arising from this approximation is likely to have little impact on 
the model predictions since the results are relatively insensitive to our assumption for survival after disease 
progression. 
The resulting PFS curves are shown in Fig. 4.  
 
Fig. 4 First-line PFS for non-resected patients: a and b - treatments from FOLFOX network; c and d - treatments from FOLFIRI network. 
CET cetuximab, FOLFIRI folinic acid + fluorouracil + irinotecan, FOLFOX folinic acid + fluorouracil + oxaliplatin, PAN panitumumab, 
PenTAG Peninsula Technology Assessment Group, PFS progression-free survival 
 
Second-line progression-free survival for non-resected patients 
We were advised by our clinical expert that it would be reasonable to assume a second-line treatment with 
FOLFIRI after first-line FOLFOX-based therapies, and second-line FOLFOX after first-line FOLFIRI-based 
treatments. Under this assumption, progression-free survival in patients on second-line treatments was modelled 
based on Tournigand et al. (2004) [35]. The authors reported Kaplan-Meier estimates of PFS for patients on 
second-line treatments with FOLFOX and FOLFIRI for a period of ~12 months. The KM curves were extracted  
using DigitizeIt [36]. Weibull distributions were fitted to each of the data sets using the method of least squares, 
with weights decreasing linearly from unity at 0 months to zero at 11 months to reflect the reduction over time 
in the number of patients at risk, observed in the RCTs (Fig. 5). One of the reasons for selecting Weibull 
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distributions for PFS was the lowest or nearly the lowest Akaike information criterion (AIC) and Bayesian 
information criterion (BIC) values. Also, it seems desirable to choose the same type of distribution for each 
treatment within the FOLFOX network and, separately, for each treatment within the FOLFIRI network, 
because the choice of distribution affects mean PFS, and we believe that substantial evidence would be required 
to choose different distributions. In addition, our clinical expert considered the resulting extrapolations 
reasonable. 
 
Fig. 5 Second-line PFS for non-resected patients. Kaplan-Meier estimates of PFS in mCRC patients [35], and Weibull 
models from the base-case analysis for: a second-line FOLFOX and b second-line FOLFIRI. FOLFIRI folinic acid + 
fluorouracil + irinotecan, FOLFOX folinic acid + fluorouracil + oxaliplatin, PenTAG Peninsula Technology Assessment 
Group, PFS progression-free survival 
 
We assumed that PFS on second-line FOLFOX and FOLFIRI is independent of first-line treatment, and 
therefore applied the same estimates in all treatment arms. The proportion of progressions due to death while on 
second-line treatment was assumed to be the same as for DFS post-resection, i.e., 6% (Section 1.1, Online 
Resource 4). 
Overall survival for non-resected patients 
Overall survival for patients who did not undergo liver resection for colorectal metastases was modelled from 
the RCTs using the same method as for PFS for non-resected patients (described under Steps A – E above). As 
for PFS, the best model fits were selected on the basis of the lowest AIC and BIC, and clinical plausibility of 
model predictions. Weibull models were found to be most appropriate (Fig. 6).  
Fig. 6 OS estimates used in the base-case analysis to model overall survival for non-resected patients: a OS for patients 
treated with CET+FOLFOX and FOLFOX (not adjusted for subsequent treatment as explained in the main text); b OS for 
patients on PAN+FOLFOX and FOLFOX (OS curves for FOLFOX are shown with and without adjustment for subsequent 
treatment); c OS for patients on CET+FOLFIRI and FOLFIRI (with and without adjustment for subsequent treatment) 
FOLFIRI folinic acid + fluorouracil + irinotecan, FOLFOX folinic acid + fluorouracil + oxaliplatin, OS overall survival 
 
The survival data reported in the RCTs was likely to be confounded by subsequent therapies, although the 
proportions of patients receiving subsequent active treatments were low. The inverse probability of censoring 
weighting (IPCW) [37] was employed by Amgen, the manufacturer of panitumumab, and the rank-preserved 
structural failure time (RPSFT) method [37] was used by Merck Serono, the manufacturer of cetuximab, to 
correct for imbalances in subsequent treatments. Due to the lack of data, survival adjustment for the 
CET+FOLFOX and FOLFOX comparison could not be performed.  
The resulting OS curves for the combination treatments with PAN+FOLFOX and CET+FOLFIRI (Fig. 6, b and 
c) lie above the OS estimates for relevant comparators, indicating that mCRC patients survive longer on the 
combination treatments with the monoclonal therapies. For CET+FOLFOX, however, predicted survival in non-
resected patients is worse compared with chemotherapy alone (Fig. 6, a), which might be due to the fact that the 
overall survival estimates were not adjusted for subsequent treatment.  
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2.2.4 Adverse events 
The network meta-analysis reported results for neutropenia, paresthesia, rash and skin conditions for all 
comparators from the FOLFOX network, and for skin conditions and diarrhea for the comparators from the 
FOLFIRI network. In our clinical expert’s opinion, not all clinically important adverse events were likely to 
have been picked up in the network meta-analysis; therefore we used an alternative approach to estimation of 
AE-related costs and QALYs, which was not reliant on incidences of adverse events from every pivotal trial. 
The methodology is detailed in Section 1.3 (Online Resource 2). 
 
2.2.5 Costs 
Unit costs were inflated to 2015/16 prices by inflating them first to 2013/14 prices using the Hospital and 
Community Health Services Pay & Prices Index (PPI) [38], and then to 2015/16 prices at a rate of 1.64% per 
annum. Where conversion from other currencies to GBP was required, International Monetary Fund purchasing 
power parity was used to convert within year (e.g., from 2010 EUR to 2010 GBP), after which inflation was 
applied. The CCEMG – EPPI-Centre Cost Converter [39] was used for the purchasing power parity conversion 
(Fig. 1 and Table 7, Online Resource 5). 
Treatment duration 
The modelled mean duration of the first-line treatments was derived from the pivotal RCTs (Table 1, Online 
Resource 5). The mean duration of the second-line treatments was based on Tournigand et al. (2004) [35] 
(Section 1.1.2, Online Resource 5) [40]. After discontinuation of the second-line treatments, non-resected 
patients were assumed to be given best-supportive care (BSC), i.e., palliative care, until death; the same 
treatment was administered to resected patients upon disease progression.  
Drug acquisition 
Drug acquisition costs were obtained, where possible, from the Commercial Medicines Unit electronic market 
information tool (CMU eMit) database [41]. For other drugs, list prices from the British National Formulary 
[42] were used in accordance with the NICE reference case [19]. The mean drug acquisition cost per patient was 
calculated as the product of the mean duration of first-line treatment, drug acquisition cost per unit time and 
dose intensity. Cetuximab dosing, based on body surface area (BSA), was estimated as in Sacco et al. (2010) 
[43] from a weight distribution of patients receiving palliative chemotherapy for CRC (provided by the lead 
author), while panitumumab dosing was directly based on this weight distribution. The drug list prices are 
shown in Table 2 (Online Resource 5).  
Drug administration 
The costs of drug administration are all borne by the NHS and PSS of administering chemotherapy to a patient, 
excluding the direct cost of drug acquisition (i.e., payments to drug manufacturers or distributors). The 
following cost components were included: delivery, pharmacy costs, infusion pump and line maintenance.  
Cetuximab and panitumumab are delivered as intravenous infusions prior to initiation of the other component of 
chemotherapy (FOLFOX or FOLFIRI) [7, 6]. FOLFOX6 and FOLFIRI consist of two hour infusions 
(leucovorin plus oxaliplatin or irinotecan), followed by bolus 5-FU and then prolonged infusional 5-FU (46 
hours). Estimated drug delivery costs were similar across the treatments, ~£400 per administration (Table 3, 
Online Resource 5). The Summary of Product Characteristics for cetuximab recommends a weekly dose of 250 
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mg/m2 BSA [6]. However, in NHS practice in England, a dose of 500 mg/m2 BSA may be given fortnightly that 
can substantially reduce the administration cost. In the analysis presented here, fortnightly administration of 
cetuximab was assumed for consistency with current clinical practice in England. 
 
Cost of liver resection 
Based on clinical advice, liver resections for mCRC were costed as very complex procedures, with 80% of them 
being open operations and the remaining 20% laparoscopic surgeries. The estimated unit cost was £10,440 per 
surgery inflated to 2015/16 prices using the average increase in the prices index (Fig. 1 and Table 7, Online 
Resource 5). Adam et al. (2004) [32] reported the mean of 1.6 liver resections per mCRC patient; this 
assumption resulted in the total cost of liver surgery of £16,704 per patient (the derivation of this cost is 
described in detail in Section 1.4, Online Resource 5). The rates of liver resection were informed by the pivotal 
RCTs: 7.3% on the CET+FOLFIRI and 2.1% on the FOLFIRI treatments (taken from the CRYSTAL trial [25]); 
the resection rates in patients on PAN+FOLFOX and FOLFOX were taken from PRIME [11] (they constitute 
Commercial-in-Confidence information and therefore not presented here [29]); the resection rate of 20.7% for 
CET+FOLFOX was estimated from OPUS and PRIME as explained in Section 1.5 (Online Resource 5).  
Other costs 
Since genetic testing is necessary for monoclonal therapies, the cost of £400 per patient was incorporated, 
assuming that 50% of patients have RAS wild type mCRC and that the cost of testing is £200 per test (personal 
communication with All Wales Medical Genetics Service and the Genetics Laboratory at Royal Devon and 
Exeter Hospital). Other costs included medical management, not covered by other cost categories; oncology 
outpatient attendances; blood tests; imaging tests (MRI and CT); colonoscopy; and palliative care (Table 5, 
Online Resource 5). The cost of managing adverse events was estimated from unit costs presented in Table 6 
(Online Resource 5). 
 
2.2.6 Utilities 
The principles, recommended by the NICE Decision Support Unit in the UK [44], were followed for the 
identification, review and synthesis of health state utility values from literature. Sources of utilities for KRAS 
WT mCRC patients only were identified. We believe, however, that utilities from the KRAS WT patient 
population would not differ significantly from those related to the RAS WT patients.  
Health state utilities from the main analysis are shown in Table 1 (Online Resource 6). The utility value for the 
“PFS (1st-line treatment)” health state (Fig. 2) was 0.767; the utility for “Progressive disease (2nd-line 
treatment)” was slightly lower, 0.762; for “Progressive disease (3rd-line BSC)” the utility was 0.641. A well-
established methodology of Ara and Brazier (2010) [45], updated to use Health Survey for England (HSE) 2012 
data [46], was employed for estimation of the post-resection progression-free utility: 
 
UHSE(2012) = 0.967981 – 0.00181 * age – 0.00001 * age2 + 0.02329 * male 
 
The utility post-resection at time 0 and age 63 was 0.83. The utility in disease progression post-successful-
resection was calculated by averaging the second- and third-line utilities, weighted by the time spent in each line 
of treatment, which resulted in the utility value in this health state of 0.67. 
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Disutilities of Grade 3/4 adverse events, shown in Table 2 (Online Resource 6), were applied for a length of one 
week in line with the approach used in Freeman et al. (2014) [47]. Grade 1/2 AEs were assumed to have no 
disutility. 
3 Results 
3.1 Base-case analysis 
A summary of the base-case results is shown in  
 
Table 1; a full breakdown is presented in Online Resource 7.  
 
Table 1 Base-case cost-effectiveness results 
 Life years  
(mean, 
undiscounted)  
QALYs  
(mean, discounted)  
Total costs  
(mean, 
discounted) 
ICER  
(Cost / QALY)  
Without adjustment for subsequent treatment 
CET+FOLFOX  2.52  1.67 £62,436  
PAN+FOLFOX 2.85 1.86 £65,526  
FOLFOX 2.35 1.55 £32,729  
CET+FOLFOX vs. FOLFOX 0.17 0.12 £29,706 £243,975 
PAN+FOLFOX vs. FOLFOX 0.50 0.31 £32,797 £106,276 
 
CET+FOLFIRI 2.90 1.92 £70,543  
FOLFIRI 2.10 1.43 £29,596  
CET+FOLFIRI vs. FOLFIRI 0.80 0.49 £40,947 £83,168 
With adjustment for subsequent treatment 
FOLFOX 2.18  1.45  £30,432  
PAN+FOLFOX vs. FOLFOX a 0.67 0.41  £35,094 £86,329 
FOLFIRI 1.82  1.26  £25,693  
CET+FOLFIRI vs. FOLFIRI b 1.08  0.66  £44,849 £68,079 
a Estimated using the results for PAN+FOLFOX for the analysis without adjustment for subsequent treatment (see above), b Estimated 
using the results for CET+FOLFIRI for the analysis without adjustment for subsequent treatment (see above). CET cetuximab, FOLFOX 
folinic acid + fluorouracil + oxaliplatin, ICER incremental cost-effectiveness ratio, PAN panitumumab, QALYs quality-adjusted life-years 
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The combination treatments with cetuximab and panitumumab appear more clinically effective and more costly 
than their comparators.  In the FOLFOX network, PAN+FOLFOX is predicted to yield the longest survival of 
2.85 years, while FOLFOX will result in the shortest survival of 2.18 with IPCW adjustment applied, and 2.35 
years without the adjustment. Patients treated with CET+FOLFIRI are predicted to live, on average, for 2.9 
years after disease diagnosis, while survival of patients on FOLFIRI is shorter: 1.82 and 2.1 years as predicted 
with and without adjustment for subsequent treatment, respectively. 
In the FOLFOX network, the PAN+FOLFOX arm accrued the most QALYs, 1.86; CET+FOLFOX resulted in 
1.67 QALYs; treatment with FOLFOX brought the QALYs of 1.45 and 1.55 with and without adjustment for 
subsequent treatment, respectively. CET+FOLFIRI was predicted to results in 1.92 QALYs; the treatment with 
FOLFIRI yielded 1.43 QALYs when adjustment for subsequent treatment was applied, and 1.26 QALYs 
without the adjustment (Table 1). 
The mean base-case ICERs ranged from £68,079 for CET+FOLFIRI vs. FOLFIRI to £243,975 for 
CET+FOLFOX vs. FOLFOX (Table 1). The major cost component was the drug acquisition costs of first-line 
treatments with cetuximab and panitumumab, £31,914 (CET+FOLFIRI) and £26,521 (PAN+FOLFOX) per 
patient, respectively (Tables 1 and 2, Online Resource 7), followed by the cost of drug administration of first-
line treatments. When zero price for cetuximab and panitumumab was assumed, PAN+FOLFOX and 
CET+FOLFIRI were not cost-effective at the willingness-to-pay (WTP) threshold of £20,000 per QALY gained 
(which represents the lower bound of a threshold range of £20,000 to £30,000 per QALY gained usually 
considered by NICE when making decisions on cost effectiveness of health technologies [19]): the respective 
ICERs were ~£22,000 and ~£21,000 per QALY gained.  
In order to improve the cost effectiveness of cetuximab and panitumumab, Merck Serono and Amgen proposed 
Patient Access Schemes (PASs) (the PASs are confidential and therefore not detailed here). When the PAS 
discounts were applied and OS was adjusted for subsequent treatment, PAN+FOLFOX and CET+FOLFIRI 
were cost-effective at the WTP of £50,000 per QALY gained [22]. Due to limited data, it was not possible to 
estimate, under the same assumptions, the ICER for CET+FOLFOX vs. FOLFOX; when OS was not adjusted 
for subsequent treatment, the ICER for this comparison exceeded £50,000 per QALY gained. 
 
3.2 Sensitivity and uncertainty analyses 
The effect on the model predictions of plausible variations in the model parameters (reported in detail in [22]) 
was explored in sensitivity analyses. One-way deterministic sensitivity analysis indicated that the cost-
effectiveness results were most sensitive to the rates of liver resection, DFS and OS post resection, PFS for non-
resected patients, and treatment duration. Probabilistic ICERs were very similar to the deterministic ICERs. 
Cost-effectiveness acceptability curves, estimated under the list prices of cetuximab and panitumumab, are 
shown in Fig. 7. At the threshold of £50,000 per QALY gained, FOLFOX is likely to be the most cost-effective 
treatment among the treatments from the FOLFOX network (with the probability of 0.981); CET+FOLFOX is 
extendedly dominated by the alternative treatment strategies. The probability of FOLFIRI being the most cost-
effective treatment in the FOLFIRI network at the threshold of £50,000 per QALY gained is equal to 1. 
  
Fig. 7 Cost-effectiveness acceptability curves from the base-case probabilistic sensitivity analysis. a FOLFOX network,   
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b FOLFIRI network. CET cetuximab, FOLFOX folinic acid + fluorouracil + oxaliplatin, PAN panitumumab, QALY quality-
adjusted life-year 
3.3 Model validation 
The economic model was validated in the following ways: 
– The model code was examined for correctness by members of PenTAG who did not build the model. 
– A simplified model that did not rely on model cycles was built to quickly identify errors in the full model. 
– The model outputs under extreme parameter values were examined for reasonableness.  
– Face validity of the model predictions was tested using numerous graphical outputs. 
4 End-of-life criteria 
The criteria of short life-expectancy of patients (normally less than 24 months), and the extension to life (of at 
least an additional 3 months) offered by a new treatment compared with those currently available in the NHS are 
considered by NICE when making decision on End-of-Life treatments. We estimated the mean life-expectancy 
of 2.18 and 1.82 months for patients on FOLFOX and FOLFIRI, respectively. Survival improvement for 
CET+FOLFOX vs. FOLFOX was under 3 months (0.17 years); this estimate, however, was obtained without 
adjustment of the overall survival for subsequent treatment.  
Given the available evidence, the End-of-Life criteria were met on the following basis:   
– The predicted mean survival for patients on both FOLFOX and FOLFIRI are close to the threshold of 24 
months, with the estimate for FOLFOX being only slightly higher than the threshold. The NICE Appraisal 
Committee concluded that from clinical- and evidence-based standpoint, these two regimes are equivalent 
in terms of efficacy, and only differ in their toxicities. Assuming that FOLFOX and FOLFIRI have similar 
efficacy, and taking into account high uncertainty in the survival estimates, the Committee concluded that 
the criterion for short life-expectancy for both treatments was met. 
– Both cetuximab and panitumumab met the extension-to-life criterion since these treatments are likely to 
prolong survival, on average, by more than three months. 
5 Discussion  
The model-based analysis presented here was conducted by PenTAG, an independent academic group not 
sponsored by any manufacturers of cetuximab and panitumumab. In our analysis, we used up-to-date clinical 
effectiveness data collected through a systemic literature review. Drug acquisition costs were obtained, where 
possible, from the Commercial Medicines Unit eMit database, which reflects the true cost of acquiring these 
drugs to the NHS in England. We explored areas of uncertainty through sensitivity and scenario analyses. 
Though the ICERs for the anti-EGFR therapies vs. chemotherapy alone altered quite substantially, none fell 
below a WTP threshold of £20,000 per QALY gained. 
Only the manufacturer of cetuximab, Merck Serono, conducted a model-based analysis as part of this appraisal. 
There are many similarities between our model and the company’s model. However, there are several important 
differences which result in very different estimates of the cost-effectiveness of cetuximab. The major differences 
relate to model assumptions on post-resection PFS and PD, and PFS in unresected patients; the rates of liver 
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resection; acquisition and administration costs; the costs of liver surgery and progressive disease post resection 
([22]). 
There are important sources of uncertainty in our economic analysis. Here, we briefly discuss only some of the 
issues. For further details, refer to our report to NICE [22]. 
 
5.1 Systematic review of effectiveness studies 
Firstly, the clinical evidence for cetuximab and panitumumab was derived from post hoc subgroup analyses for 
patients with RAS WT mCRC. It is known that subgroup analyses are frequently underpowered since subgroups 
include fewer patients than the main treatment groups. In the pivotal trials, this problem was exacerbated by a 
low number of tumor samples available for RAS WT testing, performed retrospectively, with the only exception 
being the PEAK trial where the extended RAS subgroup analysis was pre-specified.  
Secondly, in the network meta-analysis, it was not possible to construct a complete treatment network with the 
FOLFOX- and FOLFIRI-containing regimens. It was therefore not possible to compare the FOLFOX- and 
FOLFIRI-based treatments.  
Finally, no evidence on the effectiveness of panitumumab plus FOLFIRI was available at the time of the 
appraisal. Hence, it was not possible to assess the cost-effectiveness of this treatment. 
 
5.2 Economic analysis 
In the analysis, it was assumed that cetuximab is administered fortnightly (as this is current UK clinical 
practice), and that the clinical effectiveness of cetuximab would be the same as in the trials where this drug was 
administered weekly. However, there might be a difference in effectiveness between these schedules which 
might contribute to the uncertainty in the cost-effectiveness results.  
Another source of uncertainty in the model predictions is related to the PFS and OS data utilized in the analysis. 
Although the data was of high quality, as it was sourced from randomized control trials, the clinical and cost 
effectiveness of cetuximab plus FOLFOX is much more uncertain compared to the other combination 
treatments, since the number of patients in the OPUS trial was substantially lower than in the other trials. 
The uncertainty could have been increased due to the methodology employed when estimating progression-free 
and overall survival for non-resected patients. To obtain such estimates, we adjusted PFS and OS from the 
RCTs, which related to both resected and unresected patients, by use of external data from Adam et al. (2004) 
[32]. Since individual patient data from the RCTs was not available, this method should be regarded as an 
approximation only.  
In the study reported by Adam et al. (2004) [32], no patients received either cetuximab or panitumumab before 
liver resection for colorectal metastases. It is therefore possible that post-resection survival for patients initially 
treated with these drugs could differ from that reported in the source. 
The evidence is poor for the accuracy and effectiveness of companion diagnostic for testing RAS mutation 
status. Due to the paucity of data available, we assumed that these are the same in clinical practice as they are in 
the trials, which in practice would likely to result in lower effectiveness for cetuximab and panitumumab. 
The economic analysis presented here was designed for the NHS in England. However, it can easily be adapted 
for the healthcare systems of other countries. 
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6 Conclusions 
We assessed the cost effectiveness of first-line treatments with cetuximab and panitumumab for patients with 
RAS WT metastatic colorectal cancer (i.e., cancer without mutations in exons 2, 3 and 4 of KRAS and NRAS 
oncogenes), not eligible for liver resection at baseline. The cost effectiveness of these drugs in the UK has been 
previously evaluated [40]. However, this is the first study considering cetuximab and panitumumab for the RAS 
WT mCRC population in first-line settings in the context of the NHS in England.  
Based on the available evidence, cetuximab and panitumumab fulfill NICE’s End-of-Life criteria. Although the 
combination treatments with cetuximab and panitumumab have been shown to improve patient survival 
compared to treatments currently available in the NHS, under the list prices for these drugs such therapies are 
highly unlikely to represent an effective use of NHS resources; the mean base-case ICERs for the combination 
therapies exceeded common willingness-to-pay thresholds used by NICE. Under the PAS dicounts, however, 
panitumumab plus FOLFOX and cetuximab plus FOLFIRI were cost-effective at the threshold of £50,000 per 
QALY gained. After careful consideration of the available evidence and clinical experts’ opinion on the 
similarity of treatment effects of FOLFOX and FOLFIRI, the NICE Appraisal Committee concluded that the 
ICER for cetuximab plus FOLFOX vs. FOLFOX was likely to be similar to that for cetuximab plus FOLFIRI 
vs. FOLFIRI. Therefore, treatment with cetuximab plus FOLFOX was also likely to be cost-effective at £50,000 
per QALY gained. 
The Committee recommended cetuximab and panitumumab in combination with FOLFOX or FOLFIRI as first-
line End-of-Life treatments for adults with RAS WT mCRC, not eligible for liver resection at baseline. The 
drugs are recommended only when the companies provide them with the discounts agreed in the Patient Access 
Schemes. They are available through the UK Cancer Drugs Fund for treating non-mutated RAS metastatic 
colorectal cancer within the NHS in England. 
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